Findings from Peking University Broaden Understanding of Cancer Gene Therapy (Antitumor effects of oncolytic adenovirus armed with PSA-IZ-CD40L fusion gene against prostate cancer)
By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Research findings on Biotechnology are discussed in a new report. According to news reporting from Beijing, People's Republic of China, by NewsRx journalists, research stated, "Advanced prostate cancer (PC) still remains incurable. Novel immunogene therapy shows promise as treatment strategy that can target both localized and metastasized PC."
The news correspondents obtained a quote from the research from Peking University, "In this study, we have developed a PC-specific oncolytic adenovirus (Ad-PL-PPT-E1A) armed with fusion gene of prostate-specific antigen and CD40 ligand, and aimed to evaluate its therapeutic effect in vitro and in vivo. After they were rescued in human embryonic kidney 293 cells, we confirmed that Ad-PL-PPT-ElA could mediate the expression of El A efficiently and produce abundant progeny viruses in PC cells in vitro. Our data showed that Ad-PL-PPT-ElA induced apoptosis and resulted in specific oncolytic toxicity in PC cells, which was detected by Annexin-V staining and crystal violet, respectively. After stimulation with lysates, immune phenotypes and cytokines expression of human dendritic cells was detected by flow cytometry and real-time polymerase chain reaction, respectively. And, the results showed that the lysate of Ad-PL-PPT-ElA infected LNCaP cells upregulated the expression of CD80, CD83, CD86 and mRNA level of interleukin-6 (IL-6), IL-12,1L-23 and tumor necrosis factor-a significantly. In established PC3M cell-xenografted mouse models, Ad-PL-PPT-ElA treatment improved the survival and suppressed the tumor growth obviously."
According to the news reporters, the research concluded: "Ad-PL-PPT-ElA exhibited enhanced antitumor activity is a promising approach for gene therapy of advanced PC."
For more information on this research see: Antitumor effects of oncolytic adenovirus armed with PSA-IZ-CD40L fusion gene against prostate cancer. Gene Therapy, 2014;21(8):723-731. Gene Therapy can be contacted at: Nature Publishing Group, Macmillan Building, 4 Crinan St, London N1 9XW, England. (Nature Publishing Group - www.nature.com/; Gene Therapy - www.nature.com/gt/)
Our news journalists report that additional information may be obtained by contacting Y.F. Yang, Peking University, Hosp 1, Dept. of Hematol, Beijing 100871, People's Republic of China. Additional authors for this research include S.Y. Xue, Z.Z. Lu, F.J. Xiao, Y. Yin, Q.W. Zhang, C.T. Wu, H. Wang and L.S. Wang (see also Biotechnology).
Keywords for this news article include: Beijing, People's Republic of China, Asia, Adenovirus, Bioengineering, Biotechnology, Cancer Gene Therapy, Oncology, Prostate Cancer, Prostatic Neoplasms
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC